NCT00496171终止不适用
A Phase I Hexaminolevulinate (HAL) Dose-Finding Study Applying Different Formulations to the Cervix in Healthy Volunteers
Photocure1 个研究点 分布在 1 个国家开始时间: 2007年7月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 试验地点
- 1
研究概览
简要总结
The purpose of the study is to determine the most effective formulation of HAL for release of hexaminolevulinate to the cervical epithelium at different doses.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy, pre-menopausal female volunteers
排除标准
- •Acute or chronic disease which could influence the study results
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder CancerBladder CancerNCT00634621GE Healthcare283
招募中
2 期
A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard TherapyCarcinoma, HepatocellularNCT06742892Shanghai Henlius Biotech90
终止
1 期
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined CancersAdvanced Solid TumorsBreast Cancer RecurrentColorectal Cancer MetastaticRectal AdenocarcinomaEndometrial CancerColon CancerNCT06625515Accent Therapeutics17
已完成
1 期
A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell LymphomasB-cell LymphomasNCT03218072Shanghai Henlius Biotech12
终止
1 期
Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLCSmall Cell Lung CancerNCT00697476Armando Santoro, MD2